OTCMKTS:BETRF BetterLife Pharma (BETRF) Stock Price, News & Analysis → His win rate puts Warren Buffett to shame… (From Investing Daily) (Ad) Free BETRF Stock Alerts $0.08 +0.00 (+6.40%) (As of 04/26/2024 08:53 PM ET) Add Compare Share Share Today's Range$0.08▼$0.0850-Day Range$0.06▼$0.0852-Week Range$0.03▼$0.09Volume6,600 shsAverage Volume36,578 shsMarket Capitalization$8.71 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartEarningsFinancialsHeadlinesSEC FilingsShort InterestStock AnalysisChartEarningsFinancialsHeadlinesSEC FilingsShort Interest Get BetterLife Pharma alerts: Email Address Ad Colonial MetalsConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareThe latest flare-up between Israel and Palestinian militants has sent gold prices surging. Why? Because savvy investors know the endgame of the elites at play… Geopolitical crises breed uncertainty — and gold thrives on uncertainty. See why the elites are pouring billions into gold. About BetterLife Pharma Stock (OTCMKTS:BETRF)BetterLife Pharma Inc., a biotechnology company, engages in the development and commercialization of compounds for the treatment of mental disorders in Canada. It is also involved in refining and developing drug candidates from a set of complementary interferon-based technologies that have the potential to engage the immune system to fight virus infections. The company's products pipeline includes BETR-001 for the treatment of major depressive disorder, anxiety, and neuropathic pain and other neuro-psychiatric and neurological disorders; and BETR-002 to treat benzodiazepine dependency, anxiety, and neurodegenerative disorders. It is also developing MM-003, which has completed Phase II clinical trials for treatment of COVID-19 and other respiratory viral infections; and MM-001, a topical cream for local intravaginal use to treat HPV-induced cervical intraepithelial neoplasia that has completed Phase II clinical trials. The company was formerly known as Pivot Pharmaceuticals Inc. and changed its name to BetterLife Pharma Inc. in December 2019. BetterLife Pharma Inc. was incorporated in 2002 and is headquartered in Vancouver, Canada.Read More BETRF Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart BETRF Stock News HeadlinesApril 15, 2024 | finanznachrichten.deBloom Burton & Co. Inc.: BetterLife Pharma Inc. to Present at the 2024 Bloom Burton & Co. Healthcare Investor ConferenceApril 3, 2024 | finance.yahoo.comBetterLife Announces Closing of $1.168 Million Convertible Debentures to Further Advance IND-enabling Studies of its Non-hallucinogenic LSD-based Drug Candidate BETR-001April 29, 2024 | True Market Insiders (Ad)The “Next Bitcoin”? 10 CENT Crypto Set to ExplodeThe man who bought Bitcoin and Ethereum in 2017… and has spotted 44 different coins that have returned over 100%... Is now exposing a 10-cent coin that just partnered with Amazon…March 4, 2024 | financialpost.comBetterLife’s 2-Bromo-LSD for Treatment of Depression Highlighted by Carleton UniversityMarch 4, 2024 | globenewswire.comBetterLife's 2-Bromo-LSD for Treatment of Depression Highlighted by Carleton UniversityDecember 18, 2023 | finance.yahoo.comBetterLife Announces Closing of a Private PlacementNovember 30, 2023 | finance.yahoo.comBetterLife Announces Extension of WarrantsNovember 15, 2023 | finance.yahoo.comUS Patent and Trademark Office Publishes BetterLife’s Comprehensive Patent for BETR-001 and Other LSD DerivativesApril 29, 2024 | Colonial Metals (Ad)Conflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareThe latest flare-up between Israel and Palestinian militants has sent gold prices surging. Why? Because savvy investors know the endgame of the elites at play… Geopolitical crises breed uncertainty — and gold thrives on uncertainty. November 9, 2023 | morningstar.comaTyr Pharma Inc LIFESeptember 14, 2023 | finance.yahoo.comBetterLife Pharma to Host Investors Update Call on September 18, 2023September 12, 2023 | finance.yahoo.comBetterLife Obtains Favourable Animal Safety Data for Repeated Oral Dosing of BETR-001September 5, 2023 | finance.yahoo.comBetterLife Highlights BETR-001 Article in Technology Networks Drug Discovery and Announces Closing of a Private PlacementJuly 13, 2023 | finance.yahoo.comBetterLife Highlights American College of Physicians’ Updated Guidelines for Treating Depression and Announces Closing of Private PlacementJune 27, 2023 | finance.yahoo.comBetterLife Fast Tracks Its US Patent for BETR-001 and Other LSD DerivativesJune 22, 2023 | finance.yahoo.comBetterLife To Present BETR-001 Preclinical Data at the 32nd Annual Meeting of the International Behavioural Neuroscience Society (IBNS) in Niagara Falls, Ontario, CanadaJune 9, 2023 | msn.comBetterLife's Non-Hallucinogenic LSD's Clinical Studies, Braxia's Psychedelic Treatments ContinueJune 8, 2023 | finance.yahoo.comBetterLife Continues Progress on BETR-001 IND-Enabling StudiesApril 25, 2023 | finance.yahoo.comBetterLife To Present BETR-001 Preclinical Data at the 2023 Annual Meeting of the Society of Biological Psychiatry (SOBP) in San Diego, CaliforniaApril 24, 2023 | finance.yahoo.comBetterLife Pharma to Present at the 2023 Bloom Burton & Co. Healthcare Investor ConferenceApril 20, 2023 | finance.yahoo.comBetterLife To Present at the 2023 Bloom Burton & Co. Healthcare Investor ConferenceMarch 29, 2023 | proactiveinvestors.comBetterLife Pharma says BETR-001 drug candidate featured in Drug Discovery & Development articleMarch 29, 2023 | finance.yahoo.comBetterLife's Non-hallucinogenic LSD (BETR-001) For Treating Mood Disorders Highlighted in Drug Discovery & Development ArticleMarch 22, 2023 | finance.yahoo.comPromise of BetterLife's Non-hallucinogenic LSD (BETR-001) For Treating Mood Disorders Highlighted in Medical Xpress ArticleMarch 14, 2023 | finance.yahoo.comCORRECTION -- BetterLife Closes $1,857,143 of Private PlacementMarch 14, 2023 | finance.yahoo.comBetterLife Closes $1,857,143 of Private PlacementMarch 13, 2023 | msn.comPsyched: Next-Gen Compounds For Depression, Congress, Rescheduling, Benzinga Psychedelics Conference & MoreSee More Headlines Receive BETRF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for BetterLife Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today4/28/2024Next Earnings (Estimated)5/28/2024Fiscal Year End1/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolOTCMKTS:BETRF CUSIPN/A CIK1464165 Webwww.abetterlifepharma.com Phone604-221-0595FaxN/AEmployees7Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.02) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-6,900,000.00 Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-446.36% Debt Debt-to-Equity RatioN/A Current Ratio0.08 Quick Ratio0.08 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($0.05) per share Price / Book-1.53Miscellaneous Outstanding Shares113,825,000Free Float74,248,000Market Cap$8.71 million OptionableNot Optionable Beta1.39 7 Energy Stocks to Buy and Hold ForeverDo you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.Get This Free Report Key ExecutivesDr. Ahmad Doroudian Ph.D. (Age 64)Founder, CEO & Chairman Comp: $219.17kMs. Moira Ong C.A. (Age 49)CPA, CA, CFA, Chief Financial Officer Comp: $192.87kDr. Hooshmand Sheshbaradaran Ph.D. (Age 56)Chief Operating Officer Comp: $243.94kDr. Stephen SanghaCorporate Development AdvisorMr. Scott Rudge Ph.D.Head of CMCAnthony Calandra Ph.D.Head of RegulatoryDr. Abdi Ghaffari Ph.D.Head of Preclinical & ToxicologyMore ExecutivesKey CompetitorsNuvo PharmaceuticalsOTCMKTS:NRIFFNuCanaNASDAQ:NCNAAvenir Wellness SolutionsOTCMKTS:CURRMolecular TemplatesNASDAQ:MTEMVirios TherapeuticsNASDAQ:VIRIView All Competitors BETRF Stock Analysis - Frequently Asked Questions How have BETRF shares performed in 2024? BetterLife Pharma's stock was trading at $0.0480 on January 1st, 2024. Since then, BETRF stock has increased by 59.4% and is now trading at $0.0765. View the best growth stocks for 2024 here. Are investors shorting BetterLife Pharma? BetterLife Pharma saw a increase in short interest during the month of April. As of April 15th, there was short interest totaling 14,800 shares, an increase of 516.7% from the March 31st total of 2,400 shares. Based on an average daily volume of 43,000 shares, the days-to-cover ratio is currently 0.3 days. View BetterLife Pharma's Short Interest. When is BetterLife Pharma's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 28th 2024. View our BETRF earnings forecast. How do I buy shares of BetterLife Pharma? Shares of BETRF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:BETRF) was last updated on 4/29/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsHis win rate puts Warren Buffett to shame… Investing DailyDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyBiden out June 13; Kamala won’t replace him?Paradigm PressMan Who Predicted 2008: “This Will be Worse.”AltimetryJeff Bezos Just Humiliated Elon MuskInvestorPlace Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BetterLife Pharma Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
